Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)-Reference-Cited by-同舟云学术

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)

Published:2016-05-03 Issue:19 Volume:22 Page:4797-4806
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Wick Wolfgang,Gorlia Thierry,Bady Pierre,Platten Michael,van den Bent Martin J.,Taphoorn Martin J.B.,Steuve Jonathan,Brandes Alba A.,Hamou Marie-France,Wick Antje,Kosch Markus,Weller Michael,Stupp Roger,Roth Patrick,Golfinopoulos Vassilis,Frenel Jean-Sebastien,Campone Mario,Ricard Damien,Marosi Christine,Villa Salvador,Weyerbrock Astrid,Hopkins Kirsten,Homicsko Krisztian,Lhermitte Benoit,Pesce Gianfranco,Hegi Monika E.

Funder

Swiss National Science Foundation

Swiss Cancer LigueKFS

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Superoxide dismutase 1 mediates adaptation to the tumor microenvironment of glioma cells via mammalian target of rapamycin complex 1;Cell Death Discovery;2024-08-26

2. Racial Disparities in Glioblastoma Genomic Alterations: A Comprehensive Analysis of a Multi-Institution Cohort of 2390 Patients;World Neurosurgery;2024-08

3. The effects of the combination therapy of chemotherapy drugs on the fluctuations of genes involved in the TLR signaling pathway in glioblastoma multiforme therapy;Biomedicine & Pharmacotherapy;2024-08

4. No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients;Neuro-Oncology;2024-07-03

5. Recent in vitro models and tissue engineering strategies to study glioblastoma;Biotech Studies;2024-06-30